NeoGenomics, Inc. (NEO)
NasdaqCM
Price as at 30 Sept 2026, 21:45 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
NeoGenomics, Inc. trades at $18.36. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$44.93M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$34.90M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$32.02M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$12.15M · 0.0% of book
- Mario Gabelli, GAMCO INVESTORS, INC. ET AL$1.46M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in NEO
We hold 10 disclosed trades in NEO by members of Congress and executive-branch officials. The latest 5:
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 7 Aug 2026 · disclosed 10 Sept 2026
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 15 May 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 30 Apr 2026 · disclosed 1 Jul 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 7 May 2025 · disclosed 6 Jun 2025
- Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 22 Jun 2024 · disclosed 22 Aug 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own NEO?
6 of the institutions we track reported a position in NEO in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its NEO data?
Fundamentals for NEO come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:45 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NEO, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.